Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Back

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Recruiting

Open to: ALL

Age: 18.0 - N/A

Cambridge Manchester London Edinburgh

Medical Conditions

Carcinoma, Hepatocellular
Biliary Tract Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2023 Dec 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : CTLA-4/Anti-PD-1 Bispecific Antibody

Intervention Arm Group : Cohort 1A;Cohort 1B;Cohort 1C;Cohort 1D;Cohort 2B;

Intervention Type : DRUG
Intervention Description : 15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention Arm Group : Cohort 1B;Cohort 1D;Cohort 1E;

Intervention Type : DRUG
Intervention Description : Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention Arm Group : Cohort 1C;

Intervention Type : DRUG
Intervention Description : anti- PD-1 and TIGIT bispecific antibody

Intervention Arm Group : Cohort 1D;Cohort 1E;Cohort 2A;

Intervention Type : DRUG
Intervention Description : 1000 mg/m2, IV infusion

Intervention Arm Group : Cohort 2A;Cohort 2B;

Intervention Type : DRUG
Intervention Description : 25 mg/m2, IV infusion

Intervention Arm Group : Cohort 2A;Cohort 2B;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Cambridge
    CB2 0QQ
  • Research Site
    Manchester
    M20 4BX
  • Research Site
    London
    NW3 2QG
  • Research Site
    Edinburgh
    EH4 2XU

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com



The study is sponsored by AstraZeneca



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05775159
Last updated 29 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top